We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Plan B

4 December 2006 By Robert Cyran

Scrapping torcetrapib, a drug with $15bn in potential annual sales, has badly wounded the drug giant. Cutting Pfizer s sales force and other stopgap measures won t cut it. The cash rich group is likely to start buying biotechs left and right.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)